knowledge -WSS

knowledge

author：knowledge 2025-08-31 02:03:14 - browse：451

Micrograph of ulcerative colitis -- biotech coverage from STAT — Micrograph of chronic active ulcerative colitis in a biopsy specimen. Wikimedia Commons

Checkpoint inhibitors, drugs that unleash the immune system, have turned into blockbuster therapies that have transformed outcomes for some patients with deadly cancers. AltruBio, a Bay Area biotech, is betting it can help patients suffering from autoimmune and inflammatory diseases by taking the opposite tack: pumping the brakes on runaway immune responses.

The company on Tuesday announced that it has raised $225 million in a Series B venture round led by BVP Partners, with the biotech’s backers also including RA Capital Management, Cormorant Asset Management, and Soleus Capital. AltruBio plans to put that money toward advancing a drug that is already being tested in a mid-stage trial for ulcerative colitis, an increasingly competitive market in which a number of pharma companies have launched drugs.

It’s the latest example of intense investor interest in immunology-focused companies. Firms such as Paragon Therapeutics and Prometheus Laboratories have recently been at the center of financing mega-rounds, and Blackstone Life Sciences recently committed up to $300 million to launch Uniquity Bio, a company developing treatments for asthma and chronic obstructive pulmonary disease.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Guidelines to prevent youth baseball injuries need more muscle
Next article： GOP presidential candidates start declaring their loyalty

WSS

The history of OxyContin, told through Purdue Pharma documents

TB outbreak tied to bone grafts underscores testing shortcomings

Living with Fabry disease, a condition that causes chronic pain

Leqembi, other new Alzheimer’s drugs require better biomarkers

The perfect storm of weather conditions that led to the devastating wildfires in Maui

White House drug shortages task force keeps mum with Congress

Wikipedia

knowledge

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Wikipedia

In age of alternative facts, a scholarly course on calling out crap

Racing yachts have close encounter with pod of orcas near Strait of Gibraltar

Duchenne breakthrough therapy leaves behind pioneering families

An innovative path out of biotech’s “valley of death”

Hepatitis C has a cure — but many Americans still lack access to it

It's time to get medical device identifiers over the finish line

Malaria cases in Florida and Texas: Here’s what you need to know

Iowa House, Senate pass 6

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Listen: Your guide to Wegovy's blockbuster heart study

entertainment

N.Y. state detects polio case, first in the U.S. since 2013

Oak trusses raised to roof of fire

Newly revealed memo details efforts to keep Trump in power following election loss

How the political right came to back psychedelics to treat trauma

Retired US general questions alleged Putin, Prigozhin meeting

How the political right came to back psychedelics to treat trauma

focus

leisure time

entertainment

focus